Daptomycin improves outcomes regardless of vancomycin MIC in a propensity-matched analysis of methicillin-resistant Staphylococcus aureus bloodstream infections

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 10, 2016, Pages 5841-5848

  Claeys, Kimberly C ^a,e   Zasowski, Evan J ^a   Casapao, Anthony M ^a,f   Lagnf, Abdalhamid M ^a   Nagel, Jerod L ^d   Nguyen, Cynthia T ^d,g   Hallesy, Jessica A ^a   Compton, Mathew T ^a   Kaye, Keith S ^c   Levine, Donald P ^c   Davis, Susan L ^a,b   Rybak, Michael J ^a,c  

^a WAYNE STATE UNIVERSITY   (United States)

^b HENRY FORD HEALTH SYSTEM   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

^e UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^f HUSSON UNIVERSITY   (United States)

^g OCHSNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAROLINE; CREATINE KINASE; DAPTOMYCIN; RIFAMPICIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL ENDOCARDITIS; BROTH DILUTION; COHORT ANALYSIS; COMBINATION DRUG THERAPY; CONTROLLED STUDY; HOSPITAL CARE; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT FAILURE; TREATMENT OUTCOME; BACTEREMIA; CLINICAL TRIAL; DRUG EFFECTS; LENGTH OF STAY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; PATHOGENICITY; PROCEDURES; STAPHYLOCOCCAL INFECTIONS;

ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; COHORT STUDIES; DAPTOMYCIN; HUMANS; INTENSIVE CARE UNITS; LENGTH OF STAY; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME; VANCOMYCIN;

EID: 84992422358     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00227-16     Document Type: Article

References (40)

1. Sievert DM, Ricks P, Edwards JR, Schneider A, Patel J, Srinivasan A, Kallen A, Limbago B, Fridkin S, National Healthcare Safety Network (NHSN) Team and Participating NHSN Facilities. 2013. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol 34:1-14. http://dx.doi.org/10.1086/668770.
2. van Hal SJ, Jensen SO, Vaska VL, Espedido BA, Paterson DL, Gosbell IB. 2012. Predictors of mortality in Staphylococcus aureus bacteremia. Clin Microbiol Rev 25:362-386. http://dx.doi.org/10.1128/CMR.05022-11.
3. Bassetti M, Trecarichi EM, Mesini A, Spanu T, Giacobbe DR, Rossi M, Shenone E, Pascale GD, Molinari MP, Cauda R, Viscoli C, Tumbarello M. 2012. Risk factors and mortality of healthcare-associated and community-acquired Staphylococcus aureus bacteraemia. Clin Microbiol Infect 18:862-869. http://dx.doi.org/10.1111/j.1469-0691.2011.03679.x.
4. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, Rybak MJ, Talan DA, Chambers HF, Infectious Diseases Society of America. 2011. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 52:e18-e55. http://dx.doi.org/10.1093/cid/ciq146.
5. van Hal SJ, Lodise TP, Paterson DL. 2012. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis 54:755-771. http://dx.doi.org/10.1093/cid/cir935.
6. Jacob JT, DiazGranados CA. 2013. High vancomycin minimum inhibitory concentration and clinical outcomes in adults with methicillin-resistant Staphylococcus aureus infections: a meta-analysis. Int J Infect Dis 17:e93-e100. http://dx.doi.org/10.1016/j.ijid.2012.08.005.
7. Wi YM, Kim JM, Joo EJ, Ha YE, Kang CI, Ko KS, Chung DR, Song JH, Peck KR. 2012. High vancomycin minimum inhibitory concentration is a predictor of mortality in meticillin-resistant Staphylococcus aureus bacteraemia. Int J Antimicrob Agents 40:108-113. http://dx.doi.org/10.1016/j.ijantimicag.2012.04.003.
8. Honda H, Doern CD, Michael-Dunne W, Jr, Warren DK. 2011. The impact of vancomycin susceptibility on treatment outcomes among patients with methicillin resistant Staphylococcus aureus bacteremia. BMC Infect Dis 11:335. http://dx.doi.org/10.1186/1471-2334-11-335.
9. Kalil AC, Van Schooneveld TC, Fey PD, Rupp ME. 2014. Association between vancomycin minimum inhibitory concentration and mortality among patients with Staphylococcus aureus bloodstream infections: a systematic review and meta-analysis. JAMA 312:1552-1564. http://dx.doi.org/10.1001/jama.2014.6364.
10. Soriano A, Marco F, Martinez JA, Pisos E, Almela M, Dimova VP, Alamo D, Ortega M, Lopez J, Mensa J. 2008. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 46:193-200. http://dx.doi.org/10.1086/524667.
11. Fowler VG, Jr, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, Levine DP, Chambers HF, Tally FP, Vigliani GA, Cabell CH, Link AS, DeMeyer I, Filler SG, Zervos M, Cook P, Parsonnet J, Bernstein JM, Price CS, Forrest GN, Fatkenheuer G, Gareca M, Rehm SJ, Brodt HR, Tice A, Cosgrove SE, S. aureus Endocarditis and Bacteremia Study Group. 2006. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 355:653-665. http://dx.doi.org/10.1056/NEJMoa053783.
12. Rehm SJ, Boucher H, Levine D, Campion M, Eisenstein BI, Vigliani GA, Corey GR, Abrutyn E. 2008. Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates. J Antimicrob Chemother 62:1413-1421. http://dx.doi.org/10.1093/jac/dkn372.
13. Moore CL, Osaki-Kiyan P, Haque NZ, Perri MB, Donabedian S, Zervos MJ. 2012. Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study. Clin Infect Dis 54:51-58. http://dx.doi.org/10.1093/cid/cir764.
14. Murray KP, Zhao JJ, Davis SL, Kullar R, Kaye KS, Lephart P, Rybak MJ. 2013. Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration >1 mg/liter: a matched cohort study. Clin Infect Dis 56:1562-1569. http://dx.doi.org/10.1093/cid/cit112.
15. Kullar R, Davis SL, Kaye KS, Levine DP, Pogue JM, Rybak MJ. 2013. Implementation of an antimicrobial stewardship pathway with daptomycin for optimal treatment of methicillin-resistant Staphylococcus aureus bacteremia. Pharmacotherapy 33:3-10. http://dx.doi.org/10.1002/phar.1220.
16. Weston A, Golan Y, Holcroft C, Snydman DR. 2014. The efficacy of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bloodstream infection in patients with impaired renal function. Clin Infect Dis 58:1533-1539. http://dx.doi.org/10.1093/cid/ciu165.
17. Crompton JA, North DS, Yoon M, Steenbergen JN, Lamp KC, Forrest GN. 2010. Outcomes with daptomycin in the treatment of Staphylococcus aureus infections with a range of vancomycin MICs. J Antimicrob Chemother 65:1784-1791. http://dx.doi.org/10.1093/jac/dkq200.
18. Bland CM, Porr WH, Davis KA, Mansell KB. 2010. Vancomycin MIC susceptibility testing of methicillin-susceptible and methicillin-resistant Staphylococcus aureus isolates: a comparison between Etest(R) and an automated testing method. South Med J 103:1124-1128. http://dx.doi.org/10.1097/SMJ.0b013e3181efb5b1.
19. Hsu DI, Hidayat LK, Quist R, Hindler J, Karlsson A, Yusof A, Wong-Beringer A. 2008. Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus (MRSA) infections. Int J Antimicrob Agents 32:378-385. http://dx.doi.org/10.1016/j.ijantimicag.2008.05.007.
20. Chen SY, Liao CH, Wang JL, Chiang WC, Lai MS, Chie WC, Chang SC, Hsueh PR. 2014. Method-specific performance of vancomycin MIC susceptibility tests in predicting mortality of patients with methicillinresistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 69:211-218. http://dx.doi.org/10.1093/jac/dkt340.
21. Rybak MJ, Vidaillac C, Sader HS, Rhomberg PR, Salimnia H, Briski LE, Wanger A, Jones RN. 2013. Evaluation of vancomycin susceptibility testing for methicillin-resistant Staphylococcus aureus: comparison of Etest and three automated testing methods. J Clin Microbiol 51:2077-2081. http://dx.doi.org/10.1128/JCM.00448-13.
22. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. 2009. Research electronic data capture (REDCap) - a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42:377-381. http://dx.doi.org/10.1016/j.jbi.2008.08.010.
23. Kaasch AJ, Barlow G, Edgeworth JD, Fowler VG, Jr, Hellmich M, Hopkins S, Kern WV, Llewelyn MJ, Rieg S, Rodriguez-Bano J, Scarborough M, Seifert H, Soriano A, Tilley R, Torok ME, Weiss V, Wilson AP, Thwaites GE, ISAC, INSTINCT, SABG, UKCIRG, and colleagues. 2014. Staphylococcus aureus bloodstream infection: a pooled analysis of five prospective, observational studies. J Infect 68:242-251. http://dx.doi.org/10.1016/j.jinf.2013.10.015.
24. Rybak MJ, Lomaestro BM, Rotschafer JC, Moellering RC, Craig WA, Billeter M, Dalovisio JR, Levine DP. 2009. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 49:325-327. http://dx.doi.org/10.1086/600877.
25. Merck & Co. 2015. Cubicin. Highlights of prescribing information. Merck & Co., Whitehouse Station, NJ.
26. Clinical and Laboratory Standards Institute. 2014. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Clinical and Laboratory Standards Institute, Wayne, PA.
27. Zhang K, McClure J-A, Elsayed S, Louie T, Conly JM. 2008. Novel multiplex PCR assay for simultaneous identification of community-associated methicillin-resistant Staphylococcus aureus strains USA300 and USA400 and detection of mecA and Panton-Valentine leukocidin genes, with discrimination of Staphylococcus aureus from coagulase-negative staphylococci. J Clin Microbiol 46:1118-1122. http://dx.doi.org/10.1128/JCM.01309-07.
28. Milheirico C, Oliveira DC, de Lencastre H. 2007. Multiplex PCR strategy for subtyping the staphylococcal cassette chromosome mec type IV in methicillin-resistant Staphylococcus aureus: 'SCCmec IV multiplex.' J Antimicrob Chemother 60:42-48.
29. Schweizer ML, Furuno JP, Sakoulas G, Johnson JK, Harris AD, Shardell MD, McGregor JC, Thom KA, Perencevich EN. 2011. Increased mortality with accessory gene regulator (agr) dysfunction in Staphylococcus aureus among bacteremic patients. Antimicrob Agents Chemother 55:1082-1087. http://dx.doi.org/10.1128/AAC.00918-10.
30. Lodise TP, Graves J, Evans A, Graffunder E, Helmecke M, Lomaestro BM, Stellrecht K. 2008. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 52:3315-3320. http://dx.doi.org/10.1128/AAC.00113-08.
31. Kullar R, McKinnell JA, Sakoulas G. 2014. Avoiding the perfect storm: the biologic and clinical case for reevaluating the 7-day expectation for methicillin-resistant Staphylococcus aureus bacteremia before switching therapy. Clin Infect Dis 59:1455-1461. http://dx.doi.org/10.1093/cid/ciu583.
32. Claeys KC, Smith JR, Casapao AM, Mynatt RP, Avery L, Shroff A, Yamamura D, Davis SL, Rybak MJ. 2015. Impact of the combination of daptomycin and trimethoprim-sulfamethoxazole on clinical outcomes in methicillin-resistant Staphylococcus aureus infections. Antimicrob Agents Chemother 59:1969-1976. http://dx.doi.org/10.1128/AAC.04141-14.
33. Dhand A, Sakoulas G. 2014. Daptomycin in combination with other antibiotics for the treatment of complicated methicillin-resistant Staphylococcus aureus bacteremia. Clin Ther 36:1303-1316. http://dx.doi.org/10.1016/j.clinthera.2014.09.005.
34. Moise PA, Amodio-Groton M, Rashid M, Lamp KC, Hoffman-Roberts HL, Sakoulas G, Yoon MJ, Schweitzer S, Rastogi A. 2013. Multicenter evaluation of the clinical outcomes of daptomycin with and without concomitant beta-lactams in patients with Staphylococcus aureus bacteremia and mild to moderate renal impairment. Antimicrob Agents Chemother 57:1192-1200. http://dx.doi.org/10.1128/AAC.02192-12.
35. Dhand A, Bayer AS, Pogliano J, Yang SJ, Bolaris M, Nizet V, Wang G, Sakoulas G. 2011. Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding. Clin Infect Dis 53:158-163. http://dx.doi.org/10.1093/cid/cir340.
36. Kruzel MC, Lewis CT, Welsh KJ, Lewis EM, Dundas NE, Mohr JF, Armitige LY, Wanger A. 2011. Determination of vancomycin and daptomycin MICs by different testing methods for methicillin-resistant Staphylococcus aureus. J Clin Microbiol 49:2272-2273. http://dx.doi.org/10.1128/JCM.02215-10.
37. Pai MP, Neely M, Rodvold KA, Lodise TP. 2014. Innovative approaches to optimizing the delivery of vancomycin in individual patients. Adv Drug Deliv Rev 77:50-57. http://dx.doi.org/10.1016/j.addr.2014.05.016.
38. Lodise TP, Drusano GL, Zasowski E, Dihmess A, Lazariu V, Cosler L, McNutt LA. 2014. Vancomycin exposure in patients with methicillin-resistant Staphylococcus aureus bloodstream infections: how much is enough? Clin Infect Dis 59:666-675. http://dx.doi.org/10.1093/cid/ciu398.
39. Neely MN, Youn G, Jones B, Jelliffe RW, Drusano GL, Rodvold KA, Lodise TP. 2014. Are vancomycin trough concentrations adequate for optimal dosing? Antimicrob Agents Chemother 58:309-316. http://dx.doi.org/10.1128/AAC.01653-13.
40. Fowler VG Olsen MK, Corey GR, Woods CW, Cabell CH, Reller LB, Cheng AC, Dudley T, Oddone EZ. 2003. Clinical identifiers of complicated Staphylococcus aureus bacteremia. Arch Intern Med 163:2066-2072. http://dx.doi.org/10.1001/archinte.163.17.2066.